{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:58:47Z","timestamp":1771808327853,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd013715","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000}}],"reference-count":206,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013715.pub2","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T06:47:17Z","timestamp":1740034037000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis"],"prefix":"10.1002","volume":"2025","author":[{"given":"Giovanni","family":"Cagnotto","sequence":"additional","affiliation":[{"name":"Clinical Sciences Malm\u00f6; Lund University; Malm\u00f6 Sweden"},{"name":"Rheumatology; Sk\u00e5ne University Hospital; Malm\u00f6 Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten B","family":"Juhl","sequence":"additional","affiliation":[{"name":"Department of Sports Science and Clinical Biomechanics; University of Southern Denmark; Odense Denmark"},{"name":"Department of Physiotherapy and Occupational Therapy; University Hospital of Copenhagen Herlev and Gentofte; Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrik","family":"Ahlstr\u00f6m","sequence":"additional","affiliation":[{"name":"Medical faculty; University of Southern Denmark; Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"Wikstr\u00f6m","sequence":"additional","affiliation":[{"name":"Faculty of Medicine; Lund University; Lund Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Bruschettini","sequence":"additional","affiliation":[{"name":"Paediatrics, Department of Clinical Sciences Lund; Lund University, Sk\u00e5ne University Hospital; Lund Sweden"},{"name":"Cochrane Sweden, Department of Research, Development, Education and Innovation; Lund University, Sk\u00e5ne University Hospital; Lund Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingemar","family":"Petersson","sequence":"additional","affiliation":[{"name":"Institution for Clinical Sciences Lund; Lund University; Lund Sweden"},{"name":"Clinical Sciences Lund; Lund University; Lund Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lene","family":"Dreyer","sequence":"additional","affiliation":[{"name":"Center of Rheumatic Research Aalborg (CERRA), Department of Rheumatology; Aalborg University Hospital, Aalborg University; Aalborg Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Compagno","sequence":"additional","affiliation":[{"name":"Clinical Sciences Malm\u00f6; Lund University; Malm\u00f6 Sweden"},{"name":"Rheumatology; Sk\u00e5ne University Hospital; Malm\u00f6 Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"10.1002\/14651858.CD013715.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1136\/annrheumdis-2018-eular.2843","article-title":"A randomised, double-blind, parallel study to compare rates of remission (inactive disease) in patients with JIA on MTX treatment alone versus a combination of MTX and etanercept","volume":"77","author":"Alexeeva","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013715.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12969-020-00488-9","article-title":"Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial","volume":"19","author":"Alexeeva","year":"2021","journal-title":"Pediatric Rheumatology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1002\/art.38569","article-title":"A148: a multi-center, double-blind, randomized-withdrawal trial of subcutaneous golimumab in pediatric patients with active polyarticular course juvenile idiopathic arthritis despite methotrexate therapy: week 48 results","volume":"66","author":"Brunner","year":"2014","journal-title":"Arthritis & Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD013715.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","article-title":"Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial","volume":"77","author":"Brunner","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"SUPPL. 10","key":"10.1002\/14651858.CD013715.pub2-BIB0005|cit5","first-page":"S414","article-title":"A multi-center, double-blind, randomized-withdrawal trial of subcutaneous golimumab in pediatric patients with active polyarticular course juvenile idiopathic arthritis despite methotrexate therapy: week 48 results","volume":"66","author":"Brunner","year":"2014","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0006|cit6","unstructured":"A study of the safety and efficacy of CNTO 148 (golimumab) in children with juvenile idiopathic arthritis (JIA) and multiple joint involvement who have poor response to methotrexate (GO KIDS) https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2009-015019-42-Outside-EU\/EEA 2012"},{"issue":"SUPPL. 10","key":"10.1002\/14651858.CD013715.pub2-BIB0007|cit7","first-page":"S123","article-title":"Body surface area-based dosing approach produced comparable golimumab exposure across different age ranges after subcutaneous administration of golimumab in pediatric patients with juvenile idiopathic arthritis","volume":"65","author":"Leu","year":"2013","journal-title":"Arthritis and Rheumatism"},{"issue":"SUPPL. 10","key":"10.1002\/14651858.CD013715.pub2-BIB0008|cit8","first-page":"S125","article-title":"Long-term pharmacokinetics of body surface area-adjusted doses of golimumab following repeated subcutaneous administrations in pediatric patients with polyarticular juvenile idiopathic arthritis","volume":"66","author":"Leu","year":"2014","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0009|cit9","unstructured":"A study of the safety and efficacy of CNTO 148 (golimumab) in children with juvenile idiopathic arthritis (JIA) and multiple joint involvement who have poor response to methotrexate (GO KIDS) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01230827 2010"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1002\/art.38478","article-title":"GO-KIDS imaging substudy: MRI treatment response to 30 mg\/m2 Q4W subcutaneous (SC) injections of golimumab (GLM) and placebo in children with polyarticular JIA (pjia)-preliminary results of the placebo controlled portion (week 48)","volume":"66","author":"Tzaribachev","year":"2014","journal-title":"Arthritis & Rheumatology"},{"issue":"Supplement 4","key":"10.1002\/14651858.CD013715.pub2-BIB0011|cit11","first-page":"97","article-title":"Performance of disease activity measures in pediatric patients with enthesitis-related arthritis","volume":"69","author":"Burgos-Vargas","year":"2017","journal-title":"Arthritis & Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD013715.pub2-BIB0012|cit12","first-page":"1531","article-title":"Efficacy and safety of adalimumab in pediatric patients with enthesitis related arthritis","volume":"41","author":"Burgos-Vargas","year":"2014","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Burgos-Vargas R Tse S Horneff G Pangan AL Unnebrink K Anderson JK PReS-FINAL-2179: Efficacy and safety of adalimumab in pediatric patients with enthesitis related arthritis Pediatric Rheumatology 2013","DOI":"10.1186\/1546-0096-11-S2-O14"},{"issue":"SUPPL. 1","key":"10.1002\/14651858.CD013715.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"i51","DOI":"10.1093\/rheumatology\/keu094.004","article-title":"Efficacy and safety of adalimumab in paediatric patients with enthesitis related arthritis","volume":"53","author":"Burgos-Vargas","year":"2014","journal-title":"Rheumatology (United Kingdom)"},{"issue":"Supplement 10","key":"10.1002\/14651858.CD013715.pub2-BIB0015|cit15","first-page":"491","article-title":"Long-term efficacy and safety of adalimumab in pediatric patients with enthesitis related arthritis","volume":"68","author":"Burgos-Vargas","year":"2016","journal-title":"Arthritis & Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD013715.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/acr.22657","article-title":"A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis","volume":"67","author":"Burgos-Vargas","year":"2015","journal-title":"Arthritis Care & Research"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1002\/art.38414","article-title":"A3: efficacy and safety of adalimumab in pediatric patients with enthesitis related arthritis","volume":"66","author":"Burgos-Vargas","year":"2014","journal-title":"Arthritis & Rheumatology"},{"issue":"SUPPL. 10","key":"10.1002\/14651858.CD013715.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"S336","DOI":"10.1002\/art.38216","article-title":"Efficacy and safety of adalimumab in pediatric patients with enthesitis related arthritis","volume":"65","author":"Burgos-Vargas","year":"2013","journal-title":"Arthritis and Rheumatism"},{"issue":"Supplement 4","key":"10.1002\/14651858.CD013715.pub2-BIB0019|cit19","first-page":"70","article-title":"Long-term efficacy and safety of adalimumab in pediatric patients with enthesitis related arthritis","volume":"69","author":"Burgos-Vargas","year":"2017","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0020|cit20","unstructured":"A study of the efficacy and safety of adalimumab in pediatric subjects with enthesitis related arthritis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01166282"},{"issue":"1","key":"10.1002\/14651858.CD013715.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13075-022-02877-9","article-title":"A randomized, double-blind, placebo-controlled 12-week trial of infiximab in patients with juvenile-onset spondyloarthritis","volume":"24","author":"Burgos-Vargas","year":"2022","journal-title":"Arthritis Research & Therapy"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0022|cit22","unstructured":"Efficacy, safety, and tolerability study of infliximab in juvenile spondyloarthropathies https:\/\/clinicaltrials.gov\/show\/NCT00591201"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/art.39977","article-title":"Performance of disease activity measures in juvenile spondyloarthritis in a placebo controlled trial with infliximab","volume":"68","author":"Ramiro","year":"2016","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1136\/annrheumdis-2016-eular.2580","article-title":"Performance of disease activity measures in juvenile spondyloarthritis in a placebo controlled trial with infliximab","volume":"75","author":"Ramiro","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013715.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12969-017-0143-7","article-title":"Performance of disease activity measures in juvenile spondyloarthritis in a placebo controlled trial with infliximab","volume":"15","author":"Ramiro","year":"2017","journal-title":"Pediatric Rheumatology"},{"issue":"Supplement 10","key":"10.1002\/14651858.CD013715.pub2-BIB0026|cit26","first-page":"4014","article-title":"Improvement of spinal inflammation induced by etanercept in enthesitis related arthritis JIA-patients. Data of the reminder-study","volume":"68","author":"Horneff","year":"2016","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0027|cit27","first-page":"SUPPL. 10","article-title":"Induction and maintenance of remission by etanercept in enthesitis related arthritis jia-patients","volume":"67","author":"Horneff","year":"2015","journal-title":"Arthritis & Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD013715.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.39145","article-title":"Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study","volume":"67","author":"Horneff","year":"2015","journal-title":"Arthritis & Rheumatology"},{"issue":"SUPPL. 1","key":"10.1002\/14651858.CD013715.pub2-BIB0029|cit29","first-page":"S11","article-title":"Remission induction by Etanercept in enthesitis-related arthritis JIA patients (juvenile undifferentiated spondylarthropathy)-REMINDER Study","volume":"72","author":"Horneff","year":"2013","journal-title":"Zeitschrift Fur Rheumatologie"},{"issue":"11","key":"10.1002\/14651858.CD013715.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis","volume":"342","author":"Lovell","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013715.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/art.10710","article-title":"Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open-label, extended-treatment trial","volume":"48","author":"Lovell","year":"2003","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD013715.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/art.23427","article-title":"Safety and efficacy of up to eight years of continuous etanercept therapy inpatients with juvenile rheumatoid arthritis","volume":"58","author":"Lovell","year":"2008","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0033|cit33","unstructured":"Safety and efficacy of etanercept (recombinant human tumor necrosis factor receptor fusion protein [TNFR: fc]) in children with juvenile rheumatoid arthritis (JRA) https:\/\/clinicaltrials.gov\/study\/NCT03780959"},{"issue":"2","key":"10.1002\/14651858.CD013715.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"e001208","DOI":"10.1136\/rmdopen-2020-001208","article-title":"Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate","volume":"6","author":"Lovell","year":"2020","journal-title":"RMD Open"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"e001208","DOI":"10.1136\/rmdopen-2020-001208","article-title":"Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate","volume":"6","author":"Lovell","year":"2020","journal-title":"RMD Open"},{"issue":"8","key":"10.1002\/14651858.CD013715.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"A52","key":"10.1002\/14651858.CD013715.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1002\/art.38468","article-title":"The impact of adalimumab on growth in patients with juvenile idiopathic arthritis","volume":"66","author":"Lovell","year":"2014","journal-title":"Arthritis & Rheumatology"},{"issue":"SUPPL. 10","key":"10.1002\/14651858.CD013715.pub2-BIB0038|cit38","first-page":"S329","article-title":"The impact of adalimumab on growth in patients with juvenile idiopathic arthritis","volume":"64","author":"Lovell","year":"2012","journal-title":"Arthritis and Rheumatism"},{"issue":"S9","key":"10.1002\/14651858.CD013715.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1002\/art.40700","article-title":"Long-term disease control among patients with juvenile idiopathic arthritis receiving adalimumab (humira) treatment for up to six years. Conference: American College of Rheumatology\/Association of Rheumatology Health Professionals Annual Scientific Meeting 2018","volume":"70","author":"Lovell","year":"2018","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0040|cit40","first-page":"10 SUPPL. 1","article-title":"Long-term efficacy and safety of adalimumab for up to 6 years in patients with juvenile idiopathic arthritis","volume":"63","author":"Lovell","year":"2011","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0041|cit41","unstructured":"Study of human anti-TNF monoclonal antibody adalimumab in children with polyarticular juvenile idiopathic arthritis (JIA) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00048542"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"SUPPL. 2","DOI":"10.1136\/annrheumdis-2014-eular.1600","article-title":"Treating to target of minimal disease activity and normal function in polyarticular juvenile idiopathic arthritis with adalimumab: Analysis from a phase 3 clinical trial","volume":"73","author":"Ruperto","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0043|cit43","first-page":"SUPPL. 1","article-title":"Treating to target of minimal disease activity and normal function in polyarticular juvenile idiopathic arthritis with adalimumab: analysis from a phase 3 clinical trial","volume":"12","author":"Ruperto","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0044|cit44","unstructured":"A study of the safety and effectiveness of infliximab (remicade) in patients with juvenile rheumatoid arthritis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00036374"},{"issue":"9","key":"10.1002\/14651858.CD013715.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1546-0096-8-24","article-title":"The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: Analyses from a randomized, placebo-controlled trial","volume":"8","author":"Visvanathan","year":"2010","journal-title":"Pediatric Rheumatology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0047|cit47","unstructured":"Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01015547"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12969-022-00748-w","article-title":"Economic evaluation of infiximab, synthetic triple therapy and methotrexate in the treatment of newly diagnosed juvenile idiopathic arthritis","volume":"20","author":"Tarkiainen","year":"2022","journal-title":"Pediatric Rheumatology"},{"issue":"SUPPL. 2","key":"10.1002\/14651858.CD013715.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/annrheumdis-2015-eular.3291","article-title":"Health-related quality of life in patients with newly diagnosed JIA with different treatment strategies (ACUTE-JIA study)","volume":"74","author":"Tarkiainen","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Supplement 2","key":"10.1002\/14651858.CD013715.pub2-BIB0050|cit50","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-018-0265-6","article-title":"Early aggressive treatment decreases pain in patients with juvenile idiopathic arthritis","volume":"16","author":"Tarkiainen","year":"2018","journal-title":"Pediatric Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD013715.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12969-019-0370-1","article-title":"Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial","volume":"17","author":"Tarkiainen","year":"2019","journal-title":"Pediatric Rheumatology Online Journal"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12969-017-0186-9","article-title":"3 year follow-up of acute-JIA cohort-aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis","volume":"15 (Supplement","author":"Tynjala","year":"2017","journal-title":"Pediatric Rheumatology Online Journal"},{"issue":"9","key":"10.1002\/14651858.CD013715.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/ard.2010.143347","article-title":"Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial","volume":"70","author":"Tynjala","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"SUPPL. 10","key":"10.1002\/14651858.CD013715.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1186\/s12969-017-0186-9","article-title":"Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (A-CUTE-JIA): a multicenter randomized clinical trial","volume":"60","author":"Tynj\u00e4l\u00e4","year":"2009","journal-title":"Pediatric Rheumatology Online Journal"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1186\/s13063-020-04796-z","article-title":"Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST-Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial","volume":"21","author":"Acharya","year":"2020","journal-title":"Trials"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0056|cit56","unstructured":"Adalimumab in JIA-associated uveitis stopping trial (ADJUST) https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03816397"},{"issue":"3","key":"10.1002\/14651858.CD013715.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ejr.2020.02.011","article-title":"Efficacy and safety of adalimumab as the first- and second-line biologic therapy for children with juvenile idiopathic arthritis under four years of age","volume":"42","author":"Alexeeva","year":"2020","journal-title":"Egyptian Rheumatologist"},{"issue":"2","key":"10.1002\/14651858.CD013715.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"224","DOI":"10.15690\/vsp.v14i2.1291","article-title":"Long term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis without systemic manifestations","volume":"14","author":"Baranov","year":"2015","journal-title":"Voprosy Sovremennoi Pediatrii - Current Pediatrics"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0059|cit59","first-page":"2652","article-title":"The impact of adalimumab on growth in patients with pediatric enthesitis-related arthritis","volume":"70","author":"Burgos-Vargas","year":"2018","journal-title":"Arthritis & Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD013715.pub2-BIB0060|cit60","first-page":"382","article-title":"Results of treatment with etanercept in juvenile idiopathic arthritis and compared with methotrexate","volume":"56","author":"Calvo","year":"2002","journal-title":"Anales Espanoles de Pediatria"},{"issue":"8","key":"10.1002\/14651858.CD013715.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s001120050641","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis","volume":"148","author":"Emmrich","year":"2000","journal-title":"Monatsschrift fur Kinderheilkunde"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0062|cit62","unstructured":"Compassionate use study of adalimumab in children 2 to < 4 years old or age 4 and above weighing less than 15 kg with active juvenile idiopathic arthritis (JIA) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00775437"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0063|cit63","unstructured":"Study evaluating etanercept in 3 subtypes of childhood arthritis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2009-012520-84\/results"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0064|cit64","unstructured":"A study of Baricitinib in children and young adults with JIA associated eye inflammation https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2019-000119-10-FR"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD013715.pub2-BIB0065|cit65","first-page":"447","article-title":"The evaluation of efficacy of adalimumab in juvenile idiopathic arthritis-associated uveitis and chronic anterior uveitis","volume":"15","author":"Gaidar","year":"2017","journal-title":"Pediatric Rheumatology"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD013715.pub2-BIB0066|cit66","first-page":"330","article-title":"Long-term efficacy and safety of biologic therapy in children with juvenile idiopathic arthritis or non-infectious uveitis","volume":"15","author":"Gerbaux","year":"2017","journal-title":"Pediatric Rheumatology"},{"issue":"SUPPL. 10","key":"10.1002\/14651858.CD013715.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"S849","DOI":"10.1002\/art.37735","article-title":"Randomized clinical trial in pediatric rheumatology: Are parents and patients in equipoise?","volume":"64","author":"Hissink Muller","year":"2012","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1136\/annrheumdis-2018-eular.2623","article-title":"Treatment strategy study in new onset DMARD naive juvenile idiopathic arthritis first results on 24 months clinical outcome","volume":"77","author":"Hissink Muller","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"SUPPL. 2","key":"10.1002\/14651858.CD013715.pub2-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/annrheumdis-2015-eular.2048","article-title":"Three treatment strategies in recent onset DMARD naive juvenile idiopathic arthritis: initial results of the best for kids-study","volume":"74","author":"Hissink Muller","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013715.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12969-019-0362-1","article-title":"No radiographic wrist damage after treatment to target in recent-onset juvenile idiopathic arthritis","volume":"17","author":"Hissink Muller PC","year":"2019","journal-title":"Pediatric Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD013715.pub2-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12969-017-0138-4","article-title":"A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study","volume":"15","author":"Hissink Muller","year":"2017","journal-title":"Pediatric Rheumatology Online Journal"},{"issue":"Supplement 2","key":"10.1002\/14651858.CD013715.pub2-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12969-017-0185-x","article-title":"Three treatment strategies in recent onset DMARD naive juvenile idiopathic arthritis: first results of clinical outcome after 24 months","volume":"15","author":"Muller","year":"2017","journal-title":"Pediatric Rheumatology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0073|cit73","first-page":"(Supplement 10)","article-title":"Three treatment strategies in recent onset DMARD naive juvenile idiopathic arthritis: first results of clinical outcome after 24 months","volume":"69","author":"Muller","year":"2017","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0074|cit74","first-page":"O16","article-title":"Results after 24 months of drug-free inactive disease and flare frequency in juvenile idiopathic arthritis patients in a treatment-to-target strategy study","volume":"16 (Supplement","author":"Muller","year":"2018","journal-title":"Pediatric Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD013715.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/annrheumdis-2018-213902","article-title":"Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial","volume":"78","author":"Muller","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0076|cit76","unstructured":"BeSt for kids: comparing treatment strategies in juvenile idiopathic arthritis http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=NTR1574"},{"issue":"SUPPL 1","key":"10.1002\/14651858.CD013715.pub2-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1136\/annrheumdis-2021-eular.988","article-title":"Pos1300 pain in children with juvenile idiopathic arthritis treated to target: 24 month results from a randomised trial","volume":"80","author":"Spekking","year":"2021","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"SUPPL 1","key":"10.1002\/14651858.CD013715.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"P44","DOI":"10.1186\/s12969-021-00632-z","article-title":"Treatment to target reduced pain significantly in children with juvenile idiopathic arthritis participating in the best for kids study","volume":"19","author":"Spekking","year":"2021","journal-title":"Pediatric Rheumatology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ajo.2019.06.007","article-title":"Adalimumab in juvenile idiopathic arthritis-associated uveitis: 5-year follow-up of the bristol participants of the SYCAMORE trial","volume":"207","author":"Horton","year":"2019","journal-title":"American Journal of Ophthalmology"},{"issue":"SUPPL. 2","key":"10.1002\/14651858.CD013715.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"P173","DOI":"10.1186\/1546-0096-11-S2-P173","article-title":"Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to >4 years or >4 years weighing <15 kg","volume":"11","author":"Kingsbury","year":"2013","journal-title":"Pediatric Rheumatology"},{"issue":"SUPPL. 3","key":"10.1002\/14651858.CD013715.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/annrheumdis-2013-eular.2160","article-title":"Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to <4 years or >4 years weighing <15 kg","volume":"72","author":"Kingsbury","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"SUPPL. 1","key":"10.1002\/14651858.CD013715.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"i164","DOI":"10.1093\/rheumatology\/keu125.004","article-title":"Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to <4 years or >=4 years weighing <15 kg","volume":"53","author":"Kingsbury","year":"2014","journal-title":"Rheumatology (United Kingdom)"},{"issue":"SUPPL. 10","key":"10.1002\/14651858.CD013715.pub2-BIB0083|cit83","first-page":"S117","article-title":"Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to >4 years or >4 years weighing <15 kg","volume":"65","author":"Kingsbury","year":"2013","journal-title":"Arthritis and Rheumatism"},{"issue":"10","key":"10.1002\/14651858.CD013715.pub2-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1002\/art.38216","article-title":"Body surface area-based dosing approach produced comparable golimumab exposure across different age ranges after subcutaneous administration of golimumab in pediatric patients with juvenile idiopathic arthritis","volume":"65","author":"Leu","year":"2013","journal-title":"Arthritis and Rheumatism"},{"issue":"SUPPL. 10","key":"10.1002\/14651858.CD013715.pub2-BIB0085|cit85","first-page":"S125","article-title":"Long-term pharmacokinetics of body surface area-adjusted doses of golimumab following repeated subcutaneous administrations in pediatric patients with polyarticular juvenile idiopathic arthritis","volume":"66","author":"Leu","year":"2014","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0086|cit86","unstructured":"Infliximab to treat children with juvenile rheumatoid arthritis https:\/\/clinicaltrials.gov\/show\/NCT00029042"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0087|cit87","unstructured":"Efficacy of etanercept in the treatment of children with polyarticular juvenile rheumatoid arthritis European Journal of Pediatrics 2000 159 10 785 10.1007\/s004310000529"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0088|cit88","unstructured":"Effect of adalimumab for the treatment of uveitis in juvenile idiopathic arthritis https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01385826"},{"issue":"7","key":"10.1002\/14651858.CD013715.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","article-title":"ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis","volume":"77","author":"Quartier","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"(Supplement 1)","DOI":"10.1186\/s12969-017-0143-7","article-title":"Adjuvite: a double-blind, randomized, placebo-controlled trial of Adalimumab in juvenile idiopathic arthritis associated uveitis","volume":"15","author":"Quartier","year":"2017","journal-title":"Pediatric Rheumatology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/annrheumdis-2016-eular.2362","article-title":"Adjuvite: a double-blind, randomized, placebo-controlled trial of adalimumab in juvenile idiopathic arthritis associated uveitis","volume":"75","author":"Quartier","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ophtha.2018.09.043","article-title":"Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"126","author":"Hughes","year":"2018","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD013715.pub2-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ophtha.2018.09.043","article-title":"Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"126","author":"Hughes","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1745-6215-15-14","article-title":"A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)","volume":"15","author":"Ramanan","year":"2014","journal-title":"Trials"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"Article no. 14","DOI":"10.1186\/1745-6215-15-14","article-title":"A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)","volume":"15","author":"Ramanan","year":"2014","journal-title":"Trials"},{"issue":"15","key":"10.1002\/14651858.CD013715.pub2-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta23150","article-title":"Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT","volume":"23","author":"Ramanan","year":"2019","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1136\/annrheumdis-2016-eular.6053","article-title":"Adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis: the sycamore trial","volume":"Supplement 2","author":"Ramanan","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"17","key":"10.1002\/14651858.CD013715.pub2-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"(SUPPL. 10)","DOI":"10.1002\/art.39448","article-title":"A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis","volume":"67","author":"Ramanan","year":"2015","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0100|cit100","unstructured":"A study of baricitinib (LY3009104) in participants from 2 years to less than 18 years old with active JIA-associated uveitis or chronic anterior antinuclear antibody-positive uveitis https:\/\/clinicaltrials.gov\/show\/NCT04088409"},{"issue":"1","key":"10.1002\/14651858.CD013715.pub2-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1186\/s13063-021-05651-5","article-title":"Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinic","volume":"22","author":"Ramanan","year":"2021","journal-title":"Trials"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0102|cit102","first-page":"Supplement 10","article-title":"Treatment of non-infectious uveitis: a comparative long-term study between biologic therapy with adalimumab and two conventional disease-modifying antirheumatic drugs","volume":"69","author":"Romero","year":"2017","journal-title":"Arthritis & Rheumatology"},{"issue":"9636","key":"10.1002\/14651858.CD013715.pub2-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"383-91","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD013715.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1002\/art.27431","article-title":"Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis","volume":"62","author":"Ruperto","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"SUPPL. 2","key":"10.1002\/14651858.CD013715.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/1546-0096-11-S2-O4","article-title":"The impact of adalimumab on growth in patients with juvenile idiopathic arthritis","volume":"11","author":"Ruperto","year":"2013","journal-title":"Pediatric Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD013715.pub2-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1093\/rheumatology\/keab021","article-title":"Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis","volume":"60","author":"Ruperto","year":"2021","journal-title":"Rheumatology (Oxford, England)"},{"issue":"6","key":"10.1002\/14651858.CD013715.pub2-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/ard.2006.06544","article-title":"Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease","volume":"66","author":"Sharma","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0108|cit108","unstructured":"TNRF: fc to treat eye inflammation in juvenile rheumatoid arthritis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00001862"},{"issue":"1","key":"10.1002\/14651858.CD013715.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/art.20904","article-title":"A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"53","author":"Smith","year":"2005","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0110|cit110","unstructured":"Trial of early aggressive drug therapy in juvenile idiopathic arthritis https:\/\/clinicaltrials.gov\/show\/NCT00443430"},{"issue":"SUPPL. 1","key":"10.1002\/14651858.CD013715.pub2-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"A36","DOI":"10.1186\/1546-0096-10-S1-A36","article-title":"MRI findings from the trial of early aggressive therapy (TREAT) study","volume":"10","author":"Thapa","year":"2012","journal-title":"Pediatric Rheumatology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1002\/art.38216","article-title":"Go-kids imaging substudy: MRI treatment response to 30 mg\/m2 4-weekly subcutaneous injections of golimumab in children with polyarticular jia\u2014preliminary results of the open label portion","volume":"65","author":"Tzaribachev","year":"2013","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1002\/art.38478","article-title":"A62: GO-KIDS imaging substudy: MRI treatment response to 30 mg\/m2 Q4W subcutaneous (SC) injections of golimumab (GLM) and placebo in children with polyarticular JIA (pjia)\u2014preliminary results of the placebo controlled portion (week 48)","volume":"66","author":"Tzaribachev","year":"2014","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0114|cit114","unstructured":"Safety and efficacy study of etanercept (Enbrel\u00ae) in children with systemic onset juvenile rheumatoid arthritis https:\/\/clinicaltrials.gov\/show\/NCT00078806"},{"issue":"1","key":"10.1002\/14651858.CD013715.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12969-022-00739-x","article-title":"Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the \"comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS\" (STARS) trial","volume":"20","author":"Burrone","year":"2022","journal-title":"Pediatric Rheumatology Online Journal"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0116|cit116","unstructured":"Step-up and step-down therapeutic strategies in childhood arthritis (STARS) https:\/\/clinicaltrials.gov\/show\/NCT03728478"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0117|cit117","unstructured":"Etanercept plus methotrexate versus methotrexate alone in children with polyarticular course juvenile rheumatoid arthritis https:\/\/clinicaltrials.gov\/show\/NCT03781375"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/1756-185X.12962","article-title":"A randomized double-blind controlled trial of adalimumab in juvenile idiopathic arthritis","volume":"19 (Supplement","author":"Zeng","year":"2016","journal-title":"International Journal of Rheumatic Diseases"},{"issue":"Supplement 2","key":"10.1002\/14651858.CD013715.pub2-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/1756-185X.12962","article-title":"A randomized double-blind controlled clinical trial to evaluate the efficacy of recombinant human tnf-alpha receptor II fusion protein in juvenile idiopathic arthritis","volume":"19","author":"Zeng","year":"2016","journal-title":"International Journal of Rheumatic Diseases"},{"issue":"SUPPL. 98","key":"10.1002\/14651858.CD013715.pub2-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/all.12282","article-title":"A randomized controlled clinical trial to evaluate the efficacy of recombinant human tumor necrosis factor-a receptor type II fusion protein antibody in juvenile idiopathic arthritis","volume":"68","author":"Zeng","year":"2013","journal-title":"Allergy"},{"issue":"SUPPL. 2","key":"10.1002\/14651858.CD013715.pub2-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1136\/annrheumdis-2014-eular.5459","article-title":"A randomized controlled clinical trial to evaluate the efficacy of recombinant human tumor necrosis factor-alpha receptor ii fusion protein in juvenile idiopathic arthritis","volume":"73","author":"Zeng","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0122|cit122","unstructured":"Xie Y Zeng H Efficacy and safety of infliximab in juvenile idiopathic arthritis and juvenile ankylosing spondylitis: a randomised, double-blind, controlled study 13th Congress of Asian Society for Pediatric Research; Hong Kong. 23 2018 44 5"},{"issue":"Supplement 2","key":"10.1002\/14651858.CD013715.pub2-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/1756-185X.12961","article-title":"Efficacy and safety of infliximab in juvenile idiopathic arthritis and juvenile ankylosing spondylitis: a randomized, double-blind, controlled study","volume":"19","author":"Zeng","year":"2016","journal-title":"International Journal of Rheumatic Diseases"},{"issue":"SUPPL. 2","key":"10.1002\/14651858.CD013715.pub2-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1136\/annrheumdis-2014-eular.5363","article-title":"Efficacy and safety of infliximab in juvenile idiopathic arthritis and juvenile ankylosing spondylitis. Conference: Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR","volume":"73","author":"Zeng","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0125|cit125","unstructured":"An Ixekizumab study with Adalimumab reference arm in children and young adults with Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2018-000681-10-BE"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0126|cit126","unstructured":"A study of ixekizumab (LY2439821) in children with juvenile idiopathic arthritis categories of enthesitis-related arthritis (including juvenile onset ankylosing spondylitis) and juvenile psoriatic arthritis https:\/\/clinicaltrials.gov\/show\/NCT04527380"},{"issue":"3","key":"10.1002\/14651858.CD013715.pub2-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.semarthrit.2016.07.001","article-title":"Biological agents in polyarticular juvenile idiopathic arthritis: A meta-analysis of randomized withdrawal trials","volume":"46","author":"Amarilyo","year":"2016","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD013715.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00296-008-0672-y","article-title":"Health related quality of life survey about children and adolescents with juvenile idiopathic arthritis","volume":"29","author":"Amine","year":"2009","journal-title":"Rheumatology International"},{"issue":"4","key":"10.1002\/14651858.CD013715.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care & Research"},{"issue":"1","key":"10.1002\/14651858.CD013715.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013715.pub2-BIB0131|cit131","first-page":"195","article-title":"Current proposed revision of JRA criteria. JRA criteria subcommittee of the diagnostic and therapeutic criteria committee of the American Rheumatism Section of the Arthritis Foundation","volume":"20","author":"Bass","year":"1977","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD013715.pub2-BIB0132|cit132","first-page":"150","article-title":"Minimal clinically important differences of the childhood health assessment questionnaire","volume":"32","author":"Brunner","year":"2005","journal-title":"Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD013715.pub2-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial","volume":"74","author":"Brunner","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013715.pub2-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","article-title":"Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial","volume":"77","author":"Brunner","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9","key":"10.1002\/14651858.CD013715.pub2-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1093\/rheumatology\/keaa170","article-title":"The benefit-risk balance for biological agents in juvenile idiopathic arthritis: a meta-analysis of randomized clinical trials","volume":"59","author":"Cabrera","year":"2020","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"2","key":"10.1002\/14651858.CD013715.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/art.1780290216","article-title":"A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis","volume":"29","author":"Cassidy","year":"1986","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/art.34373","article-title":"Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the Juvenile Arthritis Disease Activity Score","volume":"64","author":"Consolaro","year":"2012","journal-title":"Arthritis and Rheumatism"},{"issue":"11","key":"10.1002\/14651858.CD013715.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/acr.22393","article-title":"Defining criteria for disease activity states in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score","volume":"66","author":"Consolaro","year":"2014","journal-title":"Arthritis Care & Research (Hoboken)"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0140|cit140","unstructured":"Covidence Veritas Health Innovation 2021"},{"issue":"5","key":"10.1002\/14651858.CD013715.pub2-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.semarthrit.2016.10.008","article-title":"Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review","volume":"46","author":"Davies","year":"2017","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0142|cit142","doi-asserted-by":"crossref","unstructured":"Deeks JJ Higgins JP Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from training.cochrane.org\/handbook\/archive\/v6","DOI":"10.1002\/9781119536604"},{"issue":"7","key":"10.1002\/14651858.CD013715.pub2-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/acr.21625","article-title":"Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis","volume":"64","author":"DeWitt","year":"2012","journal-title":"Arthritis Care & Research"},{"issue":"8","key":"10.1002\/14651858.CD013715.pub2-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/14740338.2019.1632288","article-title":"Comparison of adverse events of biologicals for treatment of juvenile idiopathic arthritis: a systematic review","volume":"18","author":"Diener","year":"2019","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0145|cit145","unstructured":"What is a serious adverse event? www.fda.gov\/safety\/medwatch\/howtoreport\/ucm053087.htm"},{"issue":"1","key":"10.1002\/14651858.CD013715.pub2-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12969-018-0255-8","article-title":"Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting","volume":"16","author":"Ferrara","year":"2018","journal-title":"Pediatric Rheumatology Online Journal"},{"issue":"6","key":"10.1002\/14651858.CD013715.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/art.22900","article-title":"Development and validation of a new short and simple measure of physical function for juvenile idiopathic arthritis","volume":"57","author":"Filocamo","year":"2007","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0148|cit148","unstructured":"Foeldvari I Baer J Secukinumab Is a promising treatment for patients with juvenile enthesitis related arthritis nonresponsive to anti-TNF treatment according the Juvenile Spondyloarthritis Disease Activity Index 2019 ACR\/ARP Annual Meeting 2019 acrabstracts.org\/abstract\/secukinumab-is-a-promising-treatment-for-patients-with-juvenile-enthesitis-related-arthritis-nonresponsive-to-anti-tnf-treatment-according-the-juvenile-spondyloarthritis-disease-activity-index"},{"issue":"1","key":"10.1002\/14651858.CD013715.pub2-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10067-007-0654-6","article-title":"Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence","volume":"27","author":"Gartlehner","year":"2008","journal-title":"Clinical Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD013715.pub2-BIB0150|cit150","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3389\/fphar.2016.00467","article-title":"IL-1 inhibition in systemic juvenile idiopathic arthritis","volume":"6","author":"Giancane","year":"2016","journal-title":"Frontiers in Pharmacology"},{"issue":"16","key":"10.1002\/14651858.CD013715.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1056\/NEJM199204163261602","article-title":"Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A. -U.S.S.R. double-blind, placebo-controlled trial. The pediatric rheumatology collaborative study group and the cooperative children's study group","volume":"326","author":"Giannini","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD013715.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0153|cit153","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2021"},{"issue":"10","key":"10.1002\/14651858.CD013715.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/art.1780391013","article-title":"Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy","volume":"39","author":"Grom","year":"1996","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD013715.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/rheumatology\/kel218","article-title":"Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas. The PRINTO multinational quality of life cohort study","volume":"46","author":"Gutierrez-Suarez","year":"2007","journal-title":"Rheumatology (Oxford, England)"},{"issue":"5 Suppl 61","key":"10.1002\/14651858.CD013715.pub2-BIB0156|cit156","first-page":"S122","article-title":"The use of methotrexate in children with rheumatic diseases","volume":"28","author":"Gutierrez-Suarez","year":"2010","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD013715.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/acr.21609","article-title":"Predictors of health-related quality of life in children and adolescents with juvenile idiopathic arthritis: results from a Web-based survey","volume":"64","author":"Haverman","year":"2012","journal-title":"Arthritis Care & Research"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0158|cit158","unstructured":"Higgins JPT Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0159|cit159","unstructured":"Higgins JPT Li T Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12969-023-00798-8","article-title":"Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review","volume":"21","author":"Horneff","year":"2023","journal-title":"Pediatric Rheumatology Online Journal"},{"issue":"7","key":"10.1002\/14651858.CD013715.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/art.1780340713","article-title":"Development of a disability measurement tool for juvenile rheumatoid arthritis: the Juvenile Arthritis Functional Assessment Report","volume":"34","author":"Howe","year":"1991","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD013715.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.23383","article-title":"Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study","volume":"58","author":"Kay","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD013715.pub2-BIB0163|cit163","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/rheumatology\/key306","article-title":"Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom","volume":"58","author":"Kearsley-Fleet","year":"2019","journal-title":"Rheumatology (Oxford, England)"},{"issue":"12","key":"10.1002\/14651858.CD013715.pub2-BIB0164|cit164","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-2431-12-29","article-title":"Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis","volume":"15","author":"Kemper","year":"2012","journal-title":"BMC Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD013715.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3109\/14397595.2013.843760","article-title":"Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients","volume":"24","author":"Koike","year":"2014","journal-title":"Modern Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD013715.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/BF01451007","article-title":"Study of pro-inflammatory (TNF-alpha, IL-1alpha, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters","volume":"17","author":"Kutukculer","year":"1998","journal-title":"Clinical Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD013715.pub2-BIB0167|cit167","first-page":"561","article-title":"Study of IL-2, IL-6, TNF alpha, IFN gamma and beta in the serum and synovial fluid of patients with juvenile chronic arthritis","volume":"12","author":"Lepore","year":"1994","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0168|cit168","doi-asserted-by":"crossref","unstructured":"Li T Higgins JPT Chapter 5: Collecting data. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from training.cochrane.org\/handbook\/archive\/v6","DOI":"10.1002\/9781119536604"},{"issue":"2","key":"10.1002\/14651858.CD013715.pub2-BIB0169|cit169","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40744-021-00296-x","article-title":"Efficacy and safety of anti-tnf alpha therapy for uveitis associated with juvenile idiopathic arthritis: a systematic review and meta-analysis","volume":"8","author":"Li","year":"2021","journal-title":"Rheumatology and Therapy"},{"issue":"11","key":"10.1002\/14651858.CD013715.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/anr.1780321107","article-title":"Development of a disability measurement tool for juvenile rheumatoid arthritis. The Juvenile Arthritis Functional Assessment Scale","volume":"32","author":"Lovell","year":"1989","journal-title":"Arthritis and Rheumatism"},{"issue":"11","key":"10.1002\/14651858.CD013715.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD013715.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD013715.pub2-BIB0173|cit173","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1002\/art.39234","article-title":"Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years","volume":"67","author":"Lovell","year":"2015","journal-title":"Arthritis and Rheumatology (Hoboken, NJ)"},{"issue":"2","key":"10.1002\/14651858.CD013715.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/art.1780380209","article-title":"Serum cytokines in juvenile rheumatoid arthritis: correlation with conventional inflammation parameters and clinical subtypes","volume":"38","author":"Mangge","year":"1995","journal-title":"Arthritis and Rheumatism"},{"issue":"8","key":"10.1002\/14651858.CD013715.pub2-BIB0175|cit175","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3899\/jrheum.181088","article-title":"Establishing an updated core domain set for studies in juvenile idiopathic arthritis: a report from the OMERACT 2018 JIA Workshop","volume":"46","author":"Morgan","year":"2019","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0176|cit176","unstructured":"Efficacy study of tofacitinib in pediatric JIA population clinicaltrials.gov\/ct2\/show\/NCT02592434"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0177|cit177","unstructured":"A study to evaluate the pharmacokinetics, safety, and tolerability of upadacitinib in pediatric subjects with polyarticular course juvenile idiopathic arthritis clinicaltrials.gov\/ct2\/show\/NCT03725007"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0178|cit178","unstructured":"A study of baricitinib in participants from 2 years to less than 18 years old with juvenile idiopathic arthritis (JUVE-BASIS) clinicaltrials.gov\/ct2\/show\/NCT03773978"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0179|cit179","unstructured":"Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA) clinicaltrials.gov\/ct2\/show\/NCT06222034"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0180|cit180","first-page":"379","article-title":"Polyarticular juvenile idiopathic arthritis\u2014epidemiology and management approaches","volume":"6","author":"Oberle","year":"2014","journal-title":"Journal of Clinical Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD013715.pub2-BIB0181|cit181","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1136\/annrheumdis-2012-201991","article-title":"Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons","volume":"72","author":"Otten","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD013715.pub2-BIB0182|cit182","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0183|cit183","unstructured":"Plot Digitizer Huwaldt JA SourceForge 2001"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0184|cit184","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"10401","key":"10.1002\/14651858.CD013715.pub2-BIB0185|cit185","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(23)00921-2","article-title":"Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial","volume":"402","author":"Ramanan","year":"2023","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0186|cit186","unstructured":"Review Manager 5 (RevMan 5) The Cochrane Collaboration 2020"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0187|cit187","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2025"},{"issue":"7","key":"10.1002\/14651858.CD013715.pub2-BIB0188|cit188","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/acr.22259","article-title":"Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new onset polyarticular juvenile idiopathic arthritis","volume":"66","author":"Ringold","year":"2014","journal-title":"Arthritis Care & Research"},{"issue":"7","key":"10.1002\/14651858.CD013715.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/art.20288","article-title":"A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate","volume":"50","author":"Ruperto","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"9","key":"10.1002\/14651858.CD013715.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis & Rheumatology"},{"issue":"10315","key":"10.1002\/14651858.CD013715.pub2-BIB0191|cit191","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto","year":"2021","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0192|cit192","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Akl E Chapter 11: Completing \u2018Summary of findings' tables and grading the confidence in or quality of the evidence. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0193|cit193","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"issue":"34","key":"10.1002\/14651858.CD013715.pub2-BIB0194|cit194","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20340","article-title":"The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation","volume":"20","author":"Shepherd","year":"2016","journal-title":"Health Technology Assessment (Winchester, England)"},{"issue":"5","key":"10.1002\/14651858.CD013715.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/rheumatology\/kes186","article-title":"Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach","volume":"52","author":"Simonini","year":"2013","journal-title":"Rheumatology"},{"issue":"12","key":"10.1002\/14651858.CD013715.pub2-BIB0196|cit196","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/art.1780371209","article-title":"Measurement of health status in children with juvenile rheumatoid arthritis","volume":"37","author":"Singh","year":"1994","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0197|cit197","unstructured":"Sterne JAC Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"issue":"2","key":"10.1002\/14651858.CD013715.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jbspin.2013.09.003","article-title":"Prevalence and incidence of juvenile idiopathic arthritis: a systematic review","volume":"81","author":"Thierry","year":"2014","journal-title":"Joint, Bone, Spine"},{"issue":"6","key":"10.1002\/14651858.CD013715.pub2-BIB0199|cit199","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.semarthrit.2012.10.006","article-title":"The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review","volume":"42","author":"Ungar","year":"2013","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD013715.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/1529-0131(199805)41:5<808::AID-ART6>3.0.CO;2-T","article-title":"Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group","volume":"41","author":"Rossum","year":"1998","journal-title":"Arthritis and Rheumatism"},{"issue":"11","key":"10.1002\/14651858.CD013715.pub2-BIB0201|cit201","first-page":"2290","article-title":"Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis","volume":"31","author":"Wallace","year":"2004","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD013715.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/acr.20497","article-title":"American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis","volume":"63","author":"Wallace","year":"2011","journal-title":"Arthritis Care & Research"},{"issue":"6","key":"10.1002\/14651858.CD013715.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/jamia\/ocx053","article-title":"Identifying reports of randomized controlled trials (RCTs) via a hybrid machine learning and crowdsourcing approach","volume":"24","author":"Wallace","year":"2017","journal-title":"Journal of the American Medical Informatics Association"},{"issue":"8","key":"10.1002\/14651858.CD013715.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F","article-title":"Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis","volume":"43","author":"Woo","year":"2000","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD013715.pub2-BIB0205|cit205","first-page":"536","article-title":"Development of a self-report functional status index for juvenile rheumatoid arthritis","volume":"21","author":"Wright","year":"1994","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD013715.pub2-BIB0206|cit206","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5114\/reum.2015.53133","article-title":"Prevalence of HLA-B27 antigen in patients with juvenile idiopathic arthritis","volume":"53","author":"Zuber","year":"2015","journal-title":"Reumatologia"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:06:11Z","timestamp":1771805171000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013715.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":206,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013715.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]}}}